Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer

Following US FDA Approval

30 Jan 2023

• By Ayisha Sharma

The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.

Pair of hands on the red ground of a race track, with a white number one painted on it — Menarini And Radius Have Won The Race For The First Oral SERD • Source: Shutterstock

Menarini Group/Radius Health, Inc.’s oral selective estrogen receptor degrader (SERD) Orserdu has received approval from the US Food and Drug Administration in breast cancer but only for a subset of patients, nevertheless, it is a milestone that analysts say could positively affect the rest of the pipeline.

The drug, which contains the active ingredient elacestrant, was given the green light for postmenopausal women and adult men with...